<p>Walleye Capital LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第四季度收购了 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免费报告）的新股份。这家机构投资者收购了 144,342 股该公司的股票，价值约为 8,080,000 美元。Walleye Capital LLC 在最近的报告期末持有 Rhythm Pharmaceuticals 0.23% 的股份。</p>
<p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
<ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
<p>其他几家机构投资者也调整了对该股票的持有。SRS Capital Advisors Inc. 在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 740.7%。SRS Capital Advisors Inc. 现在拥有 454 股该公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 400 股。Raleigh Capital Management Inc. 在第四季度以约 28,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。SBI Securities Co. Ltd. 在第四季度以约 37,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。R Squared Ltd 在第四季度以约 44,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。最后，KBC Group NV 在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 78.2%。KBC Group NV 现在拥有 2,251 股该公司的股票，价值 126,000 美元，此前在该期间内收购了额外的 988 股。</p>
<h2>Rhythm Pharmaceuticals 股票上涨 3.2%</h2>
<p>Rhythm Pharmaceuticals 股票周三开盘价为 62.09 美元。该公司的市值为 39.3 亿美元，市盈率为 -14.34，贝塔值为 2.32。该公司的 50 日移动平均线为 54.55 美元，200 日移动平均线为 55.43 美元。Rhythm Pharmaceuticals, Inc. 的 12 个月低点为 35.17 美元，12 个月高点为 68.58 美元。</p>
<ul>
<li>2 家生物科技公司有前景的减肥药即将推出</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 获取免费报告）最近在 2 月 26 日星期三发布了季度财报。该公司报告的每股收益为（0.72）美元，低于分析师一致预期的（0.69）美元，差额为（0.03）美元。Rhythm Pharmaceuticals 的股本回报率为 -367.36%，净利润率为 -230.07%。该公司本季度的收入为 4,183 万美元，而分析师预期为 3,848 万美元。股票分析师预计 Rhythm Pharmaceuticals, Inc. 在当前年度的每股收益将为 -4.32 美元。</p>
<h2>分析师升级和降级</h2>
<p>几位分析师最近对该公司发表了看法。Stifel Nicolaus 在 3 月 5 日星期三的研究报告中开始覆盖 Rhythm Pharmaceuticals。他们为该公司设定了 “买入” 评级和 78.00 美元的目标价。Wells Fargo &amp; Company 在 4 月 7 日星期一的报告中将 Rhythm Pharmaceuticals 的目标价从 80.00 美元上调至 91.00 美元，并给予该公司 “增持” 评级。Jefferies Financial Group 在 1 月 2 日星期四的研究报告中开始覆盖 Rhythm Pharmaceuticals 的股票。他们为该公司发布了 “买入” 评级和 80.00 美元的目标价。JMP Securities 在 12 月 23 日星期一的研究报告中重申了 “市场表现优于大盘” 的评级，并为 Rhythm Pharmaceuticals 的股票设定了 75.00 美元的目标价。最后，HC Wainwright 在 4 月 8 日星期二的报告中重申了 “买入” 评级，并将 Rhythm Pharmaceuticals 的目标价从 70.00 美元上调至 80.00 美元。根据 MarketBeat 的数据，十三位股票研究分析师对该股票给予了买入评级，目前该股票的平均评级为 “买入”，共识目标价为 74.92 美元。</p>
<p><strong>阅读我们关于 Rhythm Pharmaceuticals 的最新股票分析</strong></p>
<h2>Rhythm Pharmaceuticals 的内部买卖</h2>
<p>在相关消息中，执行副总裁 Yann Mazabraud 于 3 月 14 日星期五出售了 75,000 股该股票，交易发生在平均价格为 51.48 美元，总交易额为 3,861,000.00 美元。出售完成后，该执行副总裁现在持有 40,370 股该公司的股票，价值 2,078,247.60 美元。这代表了他们持有股票的 65.01% 的减少。该交易已在与 SEC 的法律文件中披露，相关文件可在此链接查看。此外，首席财务官 Hunter C. Smith 于 2 月 4 日星期二出售了 1,678 股 Rhythm Pharmaceuticals 的股票。该股票以平均价格 59.43 美元出售，总交易额为 99,723.54 美元。交易完成后，首席财务官现在直接持有 101,186 股该公司股票，价值 6,013,483.98 美元。这代表了他们持有股票的 1.63% 的减少。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了 146,641 股公司股票，价值 8,112,177 美元。当前 5.60% 的股票由内部人士持有。</p>
<h2>关于 Rhythm Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Rhythm Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司，专注于罕见的神经内分泌疾病。该公司的主要产品候选药物是 IMCIVREE（setmelanotide），用于治疗促黑激素前体（POMC）、前蛋白转化酶 subtilisin/kexin 类型 1、瘦素受体（LEPR）缺乏症肥胖，以及 Bardet-Biedl 综合症和 Alström 综合症。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Rhythm Pharmaceuticals</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>经纪排名在股票选择中的重要性</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Rhythm Pharmaceuticals 吗？</h2>
<p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rhythm Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RYTM

<p>Walleye Capital LLC 在第四季度收购了 144,342 股 Rhythm Pharmaceuticals, Inc.（纳斯达克代码：RYTM），价值约 808 万美元，依据最近的 SEC 文件。其他机构投资者也增加了对该公司的持股。Rhythm Pharmaceuticals 的股票开盘价为 62.09 美元，市值为 39.3 亿美元。该公司报告季度每股亏损 0.72 美元，未达到预期，但收入为 4183 万美元。分析师维持 “买入” 评级，目标价共识为 74.92 美元</p>

<p>Walleye Capital LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 144,342 shares of the company's stock, valued at approximately $8,080,000. Walleye Capital LLC owned 0.23% of Rhythm Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Walleye Capital LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第四季度收购了 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免费报告）的新股份。这家机构投资者收购了 144,342 股该公司的股票，价值约为 8,080,000 美元。Walleye Capital LLC 在最近的报告期末持有 Rhythm Pharmaceuticals 0.23% 的股份。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rhythm Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
</div><p>Several other institutional investors have also modified their holdings of the stock. SRS Capital Advisors Inc. grew its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after purchasing an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, KBC Group NV boosted its holdings in Rhythm Pharmaceuticals by 78.2% during the 4th quarter. KBC Group NV now owns 2,251 shares of the company's stock valued at $126,000 after acquiring an additional 988 shares during the period.</p>
<div class="lb-trans"><p>其他几家机构投资者也调整了对该股票的持有。SRS Capital Advisors Inc. 在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 740.7%。SRS Capital Advisors Inc. 现在拥有 454 股该公司的股票，价值 25,000 美元，此前在上个季度购买了额外的 400 股。Raleigh Capital Management Inc. 在第四季度以约 28,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。SBI Securities Co. Ltd. 在第四季度以约 37,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。R Squared Ltd 在第四季度以约 44,000 美元的价格购买了 Rhythm Pharmaceuticals 的新股份。最后，KBC Group NV 在第四季度将其在 Rhythm Pharmaceuticals 的持股增加了 78.2%。KBC Group NV 现在拥有 2,251 股该公司的股票，价值 126,000 美元，此前在该期间内收购了额外的 988 股。</p>
</div><h2>Rhythm Pharmaceuticals Stock Up 3.2 %</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股票上涨 3.2%</h2>
</div><p>Rhythm Pharmaceuticals stock opened at $62.09 on Wednesday. The firm has a market cap of $3.93 billion, a P/E ratio of -14.34 and a beta of 2.32. The business has a fifty day moving average of $54.55 and a two-hundred day moving average of $55.43. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 股票周三开盘价为 62.09 美元。该公司的市值为 39.3 亿美元，市盈率为 -14.34，贝塔值为 2.32。该公司的 50 日移动平均线为 54.55 美元，200 日移动平均线为 55.43 美元。Rhythm Pharmaceuticals, Inc. 的 12 个月低点为 35.17 美元，12 个月高点为 68.58 美元。</p>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司有前景的减肥药即将推出</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million for the quarter, compared to analysts' expectations of $38.48 million. Equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 获取免费报告）最近在 2 月 26 日星期三发布了季度财报。该公司报告的每股收益为（0.72）美元，低于分析师一致预期的（0.69）美元，差额为（0.03）美元。Rhythm Pharmaceuticals 的股本回报率为 -367.36%，净利润率为 -230.07%。该公司本季度的收入为 4,183 万美元，而分析师预期为 3,848 万美元。股票分析师预计 Rhythm Pharmaceuticals, Inc. 在当前年度的每股收益将为 -4.32 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a &#34;buy&#34; rating and a $78.00 target price for the company. Wells Fargo &amp; Company lifted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, April 7th. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They issued a &#34;buy&#34; rating and a $80.00 price objective for the company. JMP Securities reaffirmed a &#34;market outperform&#34; rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 price target (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of &#34;Buy&#34; and a consensus price target of $74.92.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发表了看法。Stifel Nicolaus 在 3 月 5 日星期三的研究报告中开始覆盖 Rhythm Pharmaceuticals。他们为该公司设定了 “买入” 评级和 78.00 美元的目标价。Wells Fargo &amp; Company 在 4 月 7 日星期一的报告中将 Rhythm Pharmaceuticals 的目标价从 80.00 美元上调至 91.00 美元，并给予该公司 “增持” 评级。Jefferies Financial Group 在 1 月 2 日星期四的研究报告中开始覆盖 Rhythm Pharmaceuticals 的股票。他们为该公司发布了 “买入” 评级和 80.00 美元的目标价。JMP Securities 在 12 月 23 日星期一的研究报告中重申了 “市场表现优于大盘” 的评级，并为 Rhythm Pharmaceuticals 的股票设定了 75.00 美元的目标价。最后，HC Wainwright 在 4 月 8 日星期二的报告中重申了 “买入” 评级，并将 Rhythm Pharmaceuticals 的目标价从 70.00 美元上调至 80.00 美元。根据 MarketBeat 的数据，十三位股票研究分析师对该股票给予了买入评级，目前该股票的平均评级为 “买入”，共识目标价为 74.92 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Rhythm Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Rhythm Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 的内部买卖</h2>
</div><p>In related news, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now owns 40,370 shares of the company's stock, valued at $2,078,247.60. This represents a 65.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Hunter C. Smith sold 1,678 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $99,723.54. Following the completion of the transaction, the chief financial officer now directly owns 101,186 shares in the company, valued at $6,013,483.98. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,641 shares of company stock valued at $8,112,177. 5.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Yann Mazabraud 于 3 月 14 日星期五出售了 75,000 股该股票，交易发生在平均价格为 51.48 美元，总交易额为 3,861,000.00 美元。出售完成后，该执行副总裁现在持有 40,370 股该公司的股票，价值 2,078,247.60 美元。这代表了他们持有股票的 65.01% 的减少。该交易已在与 SEC 的法律文件中披露，相关文件可在此链接查看。此外，首席财务官 Hunter C. Smith 于 2 月 4 日星期二出售了 1,678 股 Rhythm Pharmaceuticals 的股票。该股票以平均价格 59.43 美元出售，总交易额为 99,723.54 美元。交易完成后，首席财务官现在直接持有 101,186 股该公司股票，价值 6,013,483.98 美元。这代表了他们持有股票的 1.63% 的减少。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了 146,641 股公司股票，价值 8,112,177 美元。当前 5.60% 的股票由内部人士持有。</p>
</div><h2>About Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Rhythm Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司，专注于罕见的神经内分泌疾病。该公司的主要产品候选药物是 IMCIVREE（setmelanotide），用于治疗促黑激素前体（POMC）、前蛋白转化酶 subtilisin/kexin 类型 1、瘦素受体（LEPR）缺乏症肥胖，以及 Bardet-Biedl 综合症和 Alström 综合症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Rhythm Pharmaceuticals</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>经纪排名在股票选择中的重要性</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rhythm Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rhythm Pharmaceuticals 并不在名单上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Walleye Capital LLC 购入了 144,342 股 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM）的股票